-
1
-
-
34248203755
-
Surgical options in undifferentiated thyroid carcinoma
-
17483987 10.1007/s00268-007-0776-7
-
B.H. Lang, C.Y. Lo, Surgical options in undifferentiated thyroid carcinoma. World J. Surg. 31(5), 969-977 (2007)
-
(2007)
World J. Surg.
, vol.31
, Issue.5
, pp. 969-977
-
-
Lang, B.H.1
Lo, C.Y.2
-
2
-
-
79953237137
-
Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006
-
21186939 10.1089/thy.2010.0021
-
B. Aschebrook-Kilfoy, M.H. Ward, M.M. Sabra, S.S. Devesa, Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid 21(2), 125-134 (2011)
-
(2011)
Thyroid
, vol.21
, Issue.2
, pp. 125-134
-
-
Aschebrook-Kilfoy, B.1
Ward, M.H.2
Sabra, M.M.3
Devesa, S.S.4
-
3
-
-
65549128212
-
Anaplastic thyroid cancer: Molecular pathogenesis and emerging therapies
-
18987168 10.1677/ERC-08-0154 1:CAS:528:DC%2BD1MXptlOiu7o%3D
-
R.C. Smallridge, L.A. Marlow, J.A. Copland, Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr. Relat. Cancer 16(1), 17-44 (2009)
-
(2009)
Endocr. Relat. Cancer
, vol.16
, Issue.1
, pp. 17-44
-
-
Smallridge, R.C.1
Marlow, L.A.2
Copland, J.A.3
-
4
-
-
72749126837
-
New therapeutic advances in the management of progressive thyroid cancer
-
19218279 10.1677/ERC-08-0335 1:CAS:528:DC%2BD1MXht1GnurjO
-
J.A. Woyach, M.H. Shah, New therapeutic advances in the management of progressive thyroid cancer. Endocr. Relat. Cancer 16(3), 715-731 (2009)
-
(2009)
Endocr. Relat. Cancer
, vol.16
, Issue.3
, pp. 715-731
-
-
Woyach, J.A.1
Shah, M.H.2
-
5
-
-
77956519744
-
A phase II study of imatinib in patients with advanced anaplastic thyroid cancer
-
20718683 10.1089/thy.2010.0057 1:CAS:528:DC%2BC3cXhtFehu7jN
-
H.T. Ha, J.S. Lee, S. Urba, R.J. Koenig, J. Sisson, T. Giordano, F.P. Worden, A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 20(9), 975-980 (2010)
-
(2010)
Thyroid
, vol.20
, Issue.9
, pp. 975-980
-
-
Ha, H.T.1
Lee, J.S.2
Urba, S.3
Koenig, R.J.4
Sisson, J.5
Giordano, T.6
Worden, F.P.7
-
6
-
-
62349137638
-
A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome
-
19265494 10.1089/thy.2008.0321 1:CAS:528:DC%2BD1MXivVGkurs%3D
-
C.J. Mooney, G. Nagaiah, P. Fu, J.K. Wasman, M.M. Cooney, P.S. Savvides, J.A. Bokar, A. Dowlati, D. Wang, S.S. Agarwala, S.M. Flick, P.H. Hartman, J.D. Ortiz, P.N. Lavertu, S.C. Remick, A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 19(3), 233-240 (2009)
-
(2009)
Thyroid
, vol.19
, Issue.3
, pp. 233-240
-
-
Mooney, C.J.1
Nagaiah, G.2
Fu, P.3
Wasman, J.K.4
Cooney, M.M.5
Savvides, P.S.6
Bokar, J.A.7
Dowlati, A.8
Wang, D.9
Agarwala, S.S.10
Flick, S.M.11
Hartman, P.H.12
Ortiz, J.D.13
Lavertu, P.N.14
Remick, S.C.15
-
7
-
-
16844367677
-
Novel vascular targeting/disrupting agents: Combretastatin A4 phosphate and related compounds
-
15717941 10.1007/s11912-005-0033-x 1:CAS:528:DC%2BD28XktVamsA%3D%3D
-
M.M. Cooney, J. Ortiz, R.M. Bukowski, S.C. Remick, Novel vascular targeting/disrupting agents: combretastatin A4 phosphate and related compounds. Curr. Oncol. Rep. 7(2), 90-95 (2005)
-
(2005)
Curr. Oncol. Rep.
, vol.7
, Issue.2
, pp. 90-95
-
-
Cooney, M.M.1
Ortiz, J.2
Bukowski, R.M.3
Remick, S.C.4
-
8
-
-
77952420148
-
Proteasome inhibition: A new therapeutic strategy to cancer treatment
-
20133049 10.1016/j.canlet.2009.12.002 1:CAS:528:DC%2BC3cXlsVyitr0%3D
-
W.K. Wu, C.H. Cho, C.W. Lee, K. Wu, D. Fan, J. Yu, J.J. Sung, Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer Lett. 293(1), 15-22 (2010)
-
(2010)
Cancer Lett.
, vol.293
, Issue.1
, pp. 15-22
-
-
Wu, W.K.1
Cho, C.H.2
Lee, C.W.3
Wu, K.4
Fan, D.5
Yu, J.6
Sung, J.J.7
-
9
-
-
77953681275
-
Bortezomib
-
20072838 10.1007/978-3-642-01222-8-12 1:CAS:528:DC%2BC3cXhtlKgsLbN
-
H. Einsele, Bortezomib. Recent Results Cancer Res. 184, 173-187 (2010)
-
(2010)
Recent Results Cancer Res.
, vol.184
, pp. 173-187
-
-
Einsele, H.1
-
10
-
-
33748744702
-
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro
-
16849420 10.1210/jc.2005-2472 1:CAS:528:DC%2BD28XhtFSjtb3O
-
C.S. Mitsiades, D. McMillin, V. Kotoula, V. Poulaki, C. McMullan, J. Negri, G. Fanourakis, S. Tseleni-Balafouta, K.B. Ain, N. Mitsiades, Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J. Clin. Endocrinol. Metab. 91(10), 4013-4021 (2006)
-
(2006)
J. Clin. Endocrinol. Metab.
, vol.91
, Issue.10
, pp. 4013-4021
-
-
Mitsiades, C.S.1
McMillin, D.2
Kotoula, V.3
Poulaki, V.4
McMullan, C.5
Negri, J.6
Fanourakis, G.7
Tseleni-Balafouta, S.8
Ain, K.B.9
Mitsiades, N.10
-
11
-
-
34249851194
-
Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death
-
17327374 10.1210/jc.2006-2157 1:CAS:528:DC%2BD2sXlt1OkurY%3D
-
C. Conticello, L. Adamo, R. Giuffrida, L. Vicari, A. Zeuner, A. Eramo, G. Anastasi, L. Memeo, D. Giuffrida, G. Iannolo, M. Gulisano, R. De Maria, Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death. J. Clin. Endocrinol. Metab. 92(5), 1938-1942 (2007)
-
(2007)
J. Clin. Endocrinol. Metab.
, vol.92
, Issue.5
, pp. 1938-1942
-
-
Conticello, C.1
Adamo, L.2
Giuffrida, R.3
Vicari, L.4
Zeuner, A.5
Eramo, A.6
Anastasi, G.7
Memeo, L.8
Giuffrida, D.9
Iannolo, G.10
Gulisano, M.11
De Maria, R.12
-
12
-
-
50149093848
-
Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo
-
18616678 1:CAS:528:DC%2BD1cXhtFKntbnN
-
F. Stenner, H. Liewen, M. Zweifel, A. Weber, J. Tchinda, B. Bode, P. Samaras, S. Bauer, A. Knuth, C. Renner, Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. Cancer Sci. 99(9), 1847-1852 (2008)
-
(2008)
Cancer Sci.
, vol.99
, Issue.9
, pp. 1847-1852
-
-
Stenner, F.1
Liewen, H.2
Zweifel, M.3
Weber, A.4
Tchinda, J.5
Bode, B.6
Samaras, P.7
Bauer, S.8
Knuth, A.9
Renner, C.10
-
13
-
-
20044390030
-
Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation
-
15562011 10.1210/jc.2004-1518 1:CAS:528:DC%2BD2MXhsVCgtrg%3D
-
R. Sorrentino, S. Libertini, P.L. Pallante, G. Troncone, L. Palombini, V. Bavetsias, D. Spalletti-Cernia, P. Laccetti, S. Linardopoulos, P. Chieffi, A. Fusco, G. Portella, Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J. Clin. Endocrinol. Metab. 90, 928-935 (2005)
-
(2005)
J. Clin. Endocrinol. Metab.
, vol.90
, pp. 928-935
-
-
Sorrentino, R.1
Libertini, S.2
Pallante, P.L.3
Troncone, G.4
Palombini, L.5
Bavetsias, V.6
Spalletti-Cernia, D.7
Laccetti, P.8
Linardopoulos, S.9
Chieffi, P.10
Fusco, A.11
Portella, G.12
-
14
-
-
45849151380
-
Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines
-
18430894 10.1677/ERC-08-0021 1:CAS:528:DC%2BD1cXosVGjsbw%3D
-
Y. Arlot-Bonnemains, E. Baldini, B. Martin, J.G. Delcros, M. Toller, F. Curcio, F.S. Ambesi-Impiombato, M. D'Armiento, S. Ulisse, Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. Endocr. Relat. Cancer 15, 559-568 (2008)
-
(2008)
Endocr. Relat. Cancer
, vol.15
, pp. 559-568
-
-
Arlot-Bonnemains, Y.1
Baldini, E.2
Martin, B.3
Delcros, J.G.4
Toller, M.5
Curcio, F.6
Ambesi-Impiombato, F.S.7
D'Armiento, M.8
Ulisse, S.9
-
15
-
-
79952747231
-
Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer
-
10.1111/j.1349-7006.2011.01853.x
-
A. Wunderlich, M. Fischer, T. Schlosshauer, A. Ramaswamy, B.H. Greene, C. Brendel, D. Doll, D. Bartsch, S. Hoffmann, Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer. Cancer Sci. 102(4), 746-756 (2011)
-
(2011)
Cancer Sci.
, vol.102
, Issue.4
, pp. 746-756
-
-
Wunderlich, A.1
Fischer, M.2
Schlosshauer, T.3
Ramaswamy, A.4
Greene, B.H.5
Brendel, C.6
Doll, D.7
Bartsch, D.8
Hoffmann, S.9
-
16
-
-
0026362229
-
The molecular biology of the human anaplastic thyroid carcinoma cell
-
1726928 1:STN:280:DyaK3s3gtVSnsw%3D%3D
-
N.E. Heldin, B. Westermark, The molecular biology of the human anaplastic thyroid carcinoma cell. Thyroidology 3, 127-131 (1991)
-
(1991)
Thyroidology
, vol.3
, pp. 127-131
-
-
Heldin, N.E.1
Westermark, B.2
-
17
-
-
0029823530
-
Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo
-
10.1210/jc.81.10.3650
-
K.B. Ain, S. Tofiq, K.D. Taylor, Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J. Clin. Endocrinol. Metab. 81, 3650-3653 (1999)
-
(1999)
J. Clin. Endocrinol. Metab.
, vol.81
, pp. 3650-3653
-
-
Ain, K.B.1
Tofiq, S.2
Taylor, K.D.3
-
18
-
-
33750453810
-
Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors - A novel antiproliferative/antiangiogenic strategy in thyroid cancer
-
17053904 10.1007/s00423-006-0104-y 1:STN:280:DC%2BD28njsFGqsA%3D%3D
-
S. Hoffmann, S. Gläser, A. Wunderlich, S. Lingelbach, C. Dietrich, A. Burchert, H. Müller, M. Rothmund, A. Zielke, Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors - a novel antiproliferative/antiangiogenic strategy in thyroid cancer. Langenbecks Arch. Surg. 391(6), 589-596 (2006)
-
(2006)
Langenbecks Arch. Surg.
, vol.391
, Issue.6
, pp. 589-596
-
-
Hoffmann, S.1
Gläser, S.2
Wunderlich, A.3
Lingelbach, S.4
Dietrich, C.5
Burchert, A.6
Müller, H.7
Rothmund, M.8
Zielke, A.9
-
19
-
-
0019750732
-
Criteria for analyzing interactions between biologically active agents
-
10.1016/S0065-230X(08)60912-4
-
M.C. Berenbaum, Criteria for analyzing interactions between biologically active agents. Adv. Cancer Res. 3, 269-335 (1981)
-
(1981)
Adv. Cancer Res.
, vol.3
, pp. 269-335
-
-
Berenbaum, M.C.1
-
20
-
-
84857046133
-
Hoffmann, Targeting the proteasome as a promising therapeutic strategy in thyroid cancer
-
doi: 10.1002/jso.22113
-
A. Wunderlich, T. Arndt, M. Fischer, S. Roth, A. Ramaswamy, BH. Greene, C. Brendel, U. Hinterseher, K. Detlef, DK. Bartsch, S. Hoffmann, Targeting the proteasome as a promising therapeutic strategy in thyroid cancer. J. Surg. Oncol. 105(4), 357-364 (2012). doi: 10.1002/jso.22113
-
(2012)
J. Surg. Oncol
, vol.105
, Issue.4
, pp. 357-364
-
-
Wunderlich, A.1
Arndt, T.2
Fischer, M.3
Roth, S.4
Ramaswamy, A.5
Greene, B.H.6
Brendel, C.7
Hinterseher, U.8
Detlef, K.9
Bartsch, D.K.10
Hoffmann, S.11
-
21
-
-
72749126837
-
New therapeutic advances in the management of progressive thyroid cancer
-
10.1677/ERC-08-0335
-
J.A. Woyach, M.H. Shah, New therapeutic advances in the management of progressive thyroid cancer. Endocr. Relat. Cancer 3, 715-731 (2009)
-
(2009)
Endocr. Relat. Cancer
, vol.3
, pp. 715-731
-
-
Woyach, J.A.1
Shah, M.H.2
-
22
-
-
33748744702
-
Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro
-
16849420 10.1210/jc.2005-2472 1:CAS:528:DC%2BD28XhtFSjtb3O
-
C.S. Mitsiades, D. McMillin, V. Kotoula, V. Poulaki, C. McMullan, J. Negri, G. Fanourakis, S. Tseleni-Balafouta, K.B. Ain, N. Mitsiades, Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J. Clin. Endocrinol. Metab. 91(10), 4013-4021 (2006)
-
(2006)
J. Clin. Endocrinol. Metab.
, vol.91
, Issue.10
, pp. 4013-4021
-
-
Mitsiades, C.S.1
McMillin, D.2
Kotoula, V.3
Poulaki, V.4
McMullan, C.5
Negri, J.6
Fanourakis, G.7
Tseleni-Balafouta, S.8
Ain, K.B.9
Mitsiades, N.10
-
23
-
-
79251482174
-
AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947
-
21071467 10.1677/ERC-10-0234 1:CAS:528:DC%2BC3MXjsFWqu7w%3D
-
S. Libertini, A. Abagnale, C. Passaro, G. Botta, S. Barbato, P. Chieffi, G. Portella, AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947. Endocr. Relat. Cancer 18(1), 129-141 (2011)
-
(2011)
Endocr. Relat. Cancer
, vol.18
, Issue.1
, pp. 129-141
-
-
Libertini, S.1
Abagnale, A.2
Passaro, C.3
Botta, G.4
Barbato, S.5
Chieffi, P.6
Portella, G.7
-
24
-
-
34247259822
-
Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase
-
17360485 10.1073/pnas.0608798104 1:CAS:528:DC%2BD2sXjt12nu7o%3D
-
M.G. Manfredi, J.A. Ecsedy, K.A. Meetze, S.K. Balani, O. Burenkova, W. Chen, K.M. Galvin, K.M. Hoar, J.J. Huck, P.J. LeRoy, E.T. Ray, T.B. Sells, B. Stringer, S.G. Stroud, T.J. Vos, G.S. Weatherhead, D.R. Wysong, M. Zhang, J.B. Bolen, C.F. Claiborne, Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc. Natl. Acad. Sci. USA 104, 4106-4111 (2007)
-
(2007)
Proc. Natl. Acad. Sci. USA
, vol.104
, pp. 4106-4111
-
-
Manfredi, M.G.1
Ecsedy, J.A.2
Meetze, K.A.3
Balani, S.K.4
Burenkova, O.5
Chen, W.6
Galvin, K.M.7
Hoar, K.M.8
Huck, J.J.9
Leroy, P.J.10
Ray, E.T.11
Sells, T.B.12
Stringer, B.13
Stroud, S.G.14
Vos, T.J.15
Weatherhead, G.S.16
Wysong, D.R.17
Zhang, M.18
Bolen, J.B.19
Claiborne, C.F.20
more..
-
25
-
-
77954686021
-
A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma
-
20382844 10.1182/blood-2009-12-259523
-
G. Görgün, E. Calabrese, T. Hideshima, J. Ecsedy, G. Perrone, M. Mani, H. Ikeda, G. Bianchi, Y. Hu, D. Cirstea, L. Santo, Y.T. Tai, S. Nahar, M. Zheng, M. Bandi, R.D. Carrasco, N. Raje, N. Munshi, P. Richardson, K.C. Anderson, A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood 115(25), 5202-5213 (2010)
-
(2010)
Blood
, vol.115
, Issue.25
, pp. 5202-5213
-
-
Görgün, G.1
Calabrese, E.2
Hideshima, T.3
Ecsedy, J.4
Perrone, G.5
Mani, M.6
Ikeda, H.7
Bianchi, G.8
Hu, Y.9
Cirstea, D.10
Santo, L.11
Tai, Y.T.12
Nahar, S.13
Zheng, M.14
Bandi, M.15
Carrasco, R.D.16
Raje, N.17
Munshi, N.18
Richardson, P.19
Anderson, K.C.20
more..
-
26
-
-
70449387257
-
In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465
-
19751238 10.1111/j.1365-2141.2009.07891.x 1:CAS:528:DC%2BD1MXhs1SjtL7F
-
J.M. Negri, D.W. McMillin, J. Delmore, N. Mitsiades, P. Hayden, S. Klippel, T. Hideshima, D. Chauhan, N.C. Munshi, C.A. Buser, J. Pollard, P.G. Richardson, K.C. Anderson, C.S. Mitsiades, In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br. J. Haematol. 147(5), 672-676 (2009)
-
(2009)
Br. J. Haematol.
, vol.147
, Issue.5
, pp. 672-676
-
-
Negri, J.M.1
McMillin, D.W.2
Delmore, J.3
Mitsiades, N.4
Hayden, P.5
Klippel, S.6
Hideshima, T.7
Chauhan, D.8
Munshi, N.C.9
Buser, C.A.10
Pollard, J.11
Richardson, P.G.12
Anderson, K.C.13
Mitsiades, C.S.14
-
27
-
-
60249101252
-
Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels
-
19041685 10.1016/j.biochi.2008.10.015 1:CAS:528:DC%2BD1MXit1Kltbk%3D
-
D. Baiz, G. Pozzato, B. Dapas, R. Farra, B. Scaggiante, M. Grassi, L. Uxa, C. Giansante, C. Zennaro, G. Guarnieri, G. Grassi, Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Biochimie 91(3), 373-382 (2009)
-
(2009)
Biochimie
, vol.91
, Issue.3
, pp. 373-382
-
-
Baiz, D.1
Pozzato, G.2
Dapas, B.3
Farra, R.4
Scaggiante, B.5
Grassi, M.6
Uxa, L.7
Giansante, C.8
Zennaro, C.9
Guarnieri, G.10
Grassi, G.11
-
28
-
-
77954678999
-
Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines
-
19960346 10.1007/s00280-009-1181-8 1:CAS:528:DC%2BC3cXns1Sit74%3D
-
Y. Wang, A.K. Rishi, V.T. Puliyappadamba, S. Sharma, H. Yang, A. Tarca, Q. Ping Dou, F. Lonardo, J.C. Ruckdeschel, H.I. Pass, A. Wali, Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemother. Pharmacol. 66(3), 455-466 (2010)
-
(2010)
Cancer Chemother. Pharmacol.
, vol.66
, Issue.3
, pp. 455-466
-
-
Wang, Y.1
Rishi, A.K.2
Puliyappadamba, V.T.3
Sharma, S.4
Yang, H.5
Tarca, A.6
Ping Dou, Q.7
Lonardo, F.8
Ruckdeschel, J.C.9
Pass, H.I.10
Wali, A.11
-
29
-
-
70450243091
-
Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis
-
10.1007/s10637-008-9206-4
-
A. Brüning, P. Burger, M. Vogel, M. Rahmeh, K. Friese, M. Lenhard, A. Burges, Bortezomib treatment of ovarian cancer cells mediates endoplasmic reticulum stress, cell cycle arrest, and apoptosis. Investig. New Drugs 27(6), 543-551 (2008)
-
(2008)
Investig. New Drugs
, vol.27
, Issue.6
, pp. 543-551
-
-
Brüning, A.1
Burger, P.2
Vogel, M.3
Rahmeh, M.4
Friese, K.5
Lenhard, M.6
Burges, A.7
-
30
-
-
33748369901
-
Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells
-
16928825 10.1158/1535-7163.MCT-05-0437 1:CAS:528:DC%2BD28XosVansLg%3D
-
S.E. Canfield, K. Zhu, S.A. Williams, D.J. McConkey, Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells. Mol. Cancer Ther. 5(8), 2043-2050 (2006)
-
(2006)
Mol. Cancer Ther.
, vol.5
, Issue.8
, pp. 2043-2050
-
-
Canfield, S.E.1
Zhu, K.2
Williams, S.A.3
McConkey, D.J.4
-
31
-
-
3042562304
-
The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts
-
14749476 1:CAS:528:DC%2BD2cXntFaisg%3D%3D
-
S.T. Nawrocki, B. Sweeney-Gotsch, R. Takamori, D.J. McConkey, The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol. Cancer Ther. 3(1), 59-70 (2004)
-
(2004)
Mol. Cancer Ther.
, vol.3
, Issue.1
, pp. 59-70
-
-
Nawrocki, S.T.1
Sweeney-Gotsch, B.2
Takamori, R.3
McConkey, D.J.4
-
32
-
-
10344236486
-
Aurora-kinase inhibitors as anticancer agents
-
15573114 10.1038/nrc1502 1:CAS:528:DC%2BD2cXhtVarsLjN
-
N. Keen, S. Taylor, Aurora-kinase inhibitors as anticancer agents. Nat. Rev. Cancer 4(12), 927-936 (2004)
-
(2004)
Nat. Rev. Cancer
, vol.4
, Issue.12
, pp. 927-936
-
-
Keen, N.1
Taylor, S.2
-
33
-
-
67651146527
-
Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells
-
19584233 10.1158/1535-7163.MCT-09-0323 1:CAS:528:DC%2BD1MXosVymt7g%3D
-
P. Kaestner, A. Stolz, H. Bastians, Determinants for the efficiency of anticancer drugs targeting either Aurora-A or Aurora-B kinases in human colon carcinoma cells. Mol. Cancer Ther. 8(7), 2046-2056 (2009)
-
(2009)
Mol. Cancer Ther.
, vol.8
, Issue.7
, pp. 2046-2056
-
-
Kaestner, P.1
Stolz, A.2
Bastians, H.3
-
34
-
-
77949770773
-
MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo
-
20197380 10.1158/1541-7786.MCR-09-0300 1:CAS:528:DC%2BC3cXjt1GmsL0%3D
-
J.J. Huck, M. Zhang, A. McDonald, D. Bowman, K.M. Hoar, B. Stringer, J. Ecsedy, M.G. Manfredi, M.L. Hyer, MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo. Mol. Cancer Res. 8(3), 373-384 (2010)
-
(2010)
Mol. Cancer Res.
, vol.8
, Issue.3
, pp. 373-384
-
-
Huck, J.J.1
Zhang, M.2
McDonald, A.3
Bowman, D.4
Hoar, K.M.5
Stringer, B.6
Ecsedy, J.7
Manfredi, M.G.8
Hyer, M.L.9
-
35
-
-
0037242595
-
Function of nuclear factor kappaB in pancreatic cancer metastasis
-
12538487 1:CAS:528:DC%2BD3sXnt1Oruw%3D%3D
-
S. Fujioka, G.M. Sclabas, C. Schmidt, W.A. Frederick, Q.G. Dong, J.L. Abbruzzese, D.B. Evans, C. Baker, P.J. Chiao, Function of nuclear factor kappaB in pancreatic cancer metastasis. Clin. Cancer Res. 9(1), 346-354 (2003)
-
(2003)
Clin. Cancer Res.
, vol.9
, Issue.1
, pp. 346-354
-
-
Fujioka, S.1
Sclabas, G.M.2
Schmidt, C.3
Frederick, W.A.4
Dong, Q.G.5
Abbruzzese, J.L.6
Evans, D.B.7
Baker, C.8
Chiao, P.J.9
-
36
-
-
34447137322
-
Vitro angiogenesis and expression of nuclear factor kappaB and VEGF in high and low metastasis cell lines of salivary gland Adenoid Cystic Carcinoma. BMC Cancer. 7, 95 (2007)
-
J. Zhang, B. Peng, in vitro angiogenesis and expression of nuclear factor kappaB and VEGF in high and low metastasis cell lines of salivary gland Adenoid Cystic Carcinoma
-
(2007)
BMC Cancer
, vol.7
, pp. 95
-
-
Zhang, J.1
Peng, B.2
-
37
-
-
31544433927
-
Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells
-
16397231 10.1158/0008-5472.CAN-05-1195 1:CAS:528:DC%2BD28XhsFWhtw%3D%3D
-
A.M. Roccaro, T. Hideshima, N. Raje, S. Kumar, K. Ishitsuka, H. Yasui, N. Shiraishi, D. Ribatti, B. Nico, A. Vacca, F. Dammacco, P.G. Richardson, K.C. Anderson, Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 66(1), 184-191 (2006)
-
(2006)
Cancer Res.
, vol.66
, Issue.1
, pp. 184-191
-
-
Roccaro, A.M.1
Hideshima, T.2
Raje, N.3
Kumar, S.4
Ishitsuka, K.5
Yasui, H.6
Shiraishi, N.7
Ribatti, D.8
Nico, B.9
Vacca, A.10
Dammacco, F.11
Richardson, P.G.12
Anderson, K.C.13
-
38
-
-
79952356422
-
Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression
-
20872175 10.1007/s10456-010-9189-6 1:CAS:528:DC%2BC3cXhsVWqt7zO
-
S. Greenberger, I. Adini, E. Boscolo, J.B. Mulliken, J. Bischoff, Targeting NF-κB in infantile hemangioma-derived stem cells reduces VEGF-A expression. Angiogenesis 13(4), 327-335 (2010)
-
(2010)
Angiogenesis
, vol.13
, Issue.4
, pp. 327-335
-
-
Greenberger, S.1
Adini, I.2
Boscolo, E.3
Mulliken, J.B.4
Bischoff, J.5
-
39
-
-
80054040745
-
Effect of bortezomib on VEGF gene expression of endothelial cell line HMEC-1 and its possible mechanisms
-
20561442 1:CAS:528:DC%2BC3cXht1yltr7P
-
L.X. Xue, M. Jiang, L.Q. Xie, C.G. Ruan, Effect of bortezomib on VEGF gene expression of endothelial cell line HMEC-1 and its possible mechanisms. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 18(3), 744-748 (2010)
-
(2010)
Zhongguo Shi Yan Xue Ye Xue Za Zhi.
, vol.18
, Issue.3
, pp. 744-748
-
-
Xue, L.X.1
Jiang, M.2
Xie, L.Q.3
Ruan, C.G.4
-
40
-
-
84979846419
-
The effect of bortezomib on migration of endothelial cells and angiogenesis
-
21122357 1:CAS:528:DC%2BC3cXht1SgsbbJ
-
L.X. Xue, M. Jiang, L.Q. Xie, C.G. Ruan, The effect of bortezomib on migration of endothelial cells and angiogenesis. Zhonghua Xue Ye Xue Za Zhi. 31(6), 403-406 (2010)
-
(2010)
Zhonghua Xue Ye Xue Za Zhi.
, vol.31
, Issue.6
, pp. 403-406
-
-
Xue, L.X.1
Jiang, M.2
Xie, L.Q.3
Ruan, C.G.4
-
41
-
-
0036735298
-
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model
-
12208752 1:CAS:528:DC%2BD38Xmslyksrw%3D
-
R. LeBlanc, L.P. Catley, T. Hideshima, S. Lentzsch, C.S. Mitsiades, N. Mitsiades, D. Neuberg, O. Goloubeva, C.S. Pien, J. Adams, D. Gupta, P.G. Richardson, N.C. Munshi, K.C. Anderson, Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62(17), 4996-5000 (2002)
-
(2002)
Cancer Res.
, vol.62
, Issue.17
, pp. 4996-5000
-
-
Leblanc, R.1
Catley, L.P.2
Hideshima, T.3
Lentzsch, S.4
Mitsiades, C.S.5
Mitsiades, N.6
Neuberg, D.7
Goloubeva, O.8
Pien, C.S.9
Adams, J.10
Gupta, D.11
Richardson, P.G.12
Munshi, N.C.13
Anderson, K.C.14
-
42
-
-
33747443493
-
Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis
-
16912267 10.1093/jnci/djj309 1:CAS:528:DC%2BD28Xotl2ktrY%3D
-
C. Brignole, D. Marimpietri, F. Pastorino, B. Nico, D. Di Paolo, M. Cioni, F. Piccardi, M. Cilli, A. Pezzolo, M.V. Corrias, V. Pistoia, D. Ribatti, G. Pagnan, M. Ponzoni, Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. J. Natl. Cancer Inst. 98(16), 1142-1157 (2006)
-
(2006)
J. Natl. Cancer Inst.
, vol.98
, Issue.16
, pp. 1142-1157
-
-
Brignole, C.1
Marimpietri, D.2
Pastorino, F.3
Nico, B.4
Di Paolo, D.5
Cioni, M.6
Piccardi, F.7
Cilli, M.8
Pezzolo, A.9
Corrias, M.V.10
Pistoia, V.11
Ribatti, D.12
Pagnan, G.13
Ponzoni, M.14
-
43
-
-
34547582308
-
Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma
-
17689684 10.1016/j.surg.2007.04.012
-
J.B. Hamner, P.V. Dickson, T.L. Sims, J. Zhou, Y. Spence, C.Y. Ng, A.M. Davidoff, Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma. Surgery 142(2), 185-191 (2007)
-
(2007)
Surgery
, vol.142
, Issue.2
, pp. 185-191
-
-
Hamner, J.B.1
Dickson, P.V.2
Sims, T.L.3
Zhou, J.4
Spence, Y.5
Ng, C.Y.6
Davidoff, A.M.7
-
44
-
-
80052782931
-
ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin
-
21159048 10.1111/j.1447-0756.2010.01414.x 1:CAS:528:DC%2BC3MXovVyhsrY%3D
-
L. Zhang, S. Zhang, ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin. J. Obstet. Gynaecol. Res. 37(6), 591-600 (2011)
-
(2011)
J. Obstet. Gynaecol. Res.
, vol.37
, Issue.6
, pp. 591-600
-
-
Zhang, L.1
Zhang, S.2
|